Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.
Jenkins DW, Ross S, Veldman-Jones M, Foltz IN, Clavette BC, Manchulenko K, Eberlein C, Kendrew J, Petteruti P, Cho S, Damschroder M, Peng L, Baker D, Smith NR, Weir HM, Blakey DC, Bedian V, Barry ST. Jenkins DW, et al. Among authors: blakey dc. Mol Cancer Ther. 2012 Aug;11(8):1650-60. doi: 10.1158/1535-7163.MCT-11-1027. Epub 2012 Jun 7. Mol Cancer Ther. 2012. PMID: 22679110
A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo.
Eberlein C, Kendrew J, McDaid K, Alfred A, Kang JS, Jacobs VN, Ross SJ, Rooney C, Smith NR, Rinkenberger J, Cao A, Churchman A, Marshall JF, Weir HM, Bedian V, Blakey DC, Foltz IN, Barry ST. Eberlein C, et al. Among authors: blakey dc. Oncogene. 2013 Sep 12;32(37):4406-16. doi: 10.1038/onc.2012.460. Epub 2012 Oct 29. Oncogene. 2013. PMID: 23108397
A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models.
Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, Pablo L, McCoon P, Bedian V, Blakey DC. Brown JL, et al. Among authors: blakey dc. Mol Cancer Ther. 2010 Jan;9(1):145-56. doi: 10.1158/1535-7163.MCT-09-0554. Epub 2010 Jan 6. Mol Cancer Ther. 2010. PMID: 20053776
Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling.
Michaud NR, Wang Y, McEachern KA, Jordan JJ, Mazzola AM, Hernandez A, Jalla S, Chesebrough JW, Hynes MJ, Belmonte MA, Wang L, Kang JS, Jovanovic J, Laing N, Jenkins DW, Hurt E, Liang M, Frantz C, Hollingsworth RE, Simeone DM, Blakey DC, Bedian V. Michaud NR, et al. Among authors: blakey dc. Mol Cancer Ther. 2014 Feb;13(2):386-98. doi: 10.1158/1535-7163.MCT-13-0420. Epub 2013 Dec 16. Mol Cancer Ther. 2014. PMID: 24344235
Identification of novel vascular targets in lung cancer.
Zhuang X, Herbert JM, Lodhia P, Bradford J, Turner AM, Newby PM, Thickett D, Naidu U, Blakey D, Barry S, Cross DA, Bicknell R. Zhuang X, et al. Br J Cancer. 2015 Feb 3;112(3):485-94. doi: 10.1038/bjc.2014.626. Epub 2014 Dec 23. Br J Cancer. 2015. PMID: 25535734 Free PMC article.
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.
Ross SJ, Revenko AS, Hanson LL, Ellston R, Staniszewska A, Whalley N, Pandey SK, Revill M, Rooney C, Buckett LK, Klein SK, Hudson K, Monia BP, Zinda M, Blakey DC, Lyne PD, Macleod AR. Ross SJ, et al. Among authors: blakey dc. Sci Transl Med. 2017 Jun 14;9(394):eaal5253. doi: 10.1126/scitranslmed.aal5253. Sci Transl Med. 2017. PMID: 28615361
89 results